LCZ696, a First‐in‐Class Angiotensin Receptor‐Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension

The safety of LCZ696, a novel angiotensin receptor‐neprilysin inhibitor, was evaluated for the first time in patients with severe hypertension in this 8‐week, multicenter, open‐label study. Thirty‐five Japanese patients with either office systolic blood pressure (SBP) ≥180 mm Hg or diastolic blood p...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Hypertens (Greenwich)
Asıl Yazarlar: Kario, Kazuomi, Tamaki, Yuko, Okino, Naoko, Gotou, Hiromi, Zhu, Min, Zhang, Jack
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2015
Konular:
Original Papers
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8032009/
https://ncbi.nlm.nih.gov/pubmed/26402918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jch.12667
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller